Monoamine oxidase-B (MAO-B) inhibitors: Implications for disease-modification in Parkinson's disease

Translational Neurodegeneration

Volumn 2, Issue 1, 2013, Pages

  Teo, Kay Cheong ^a   Ho, Shu Leong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Disease modification; Monoamine oxidase B inhibitors; Neuroprotection; Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

ALPHA TOCOPHEROL; DOPAMINE RECEPTOR STIMULATING AGENT; LAZABEMIDE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; PRAMIPEXOLE; RASAGILINE; SELEGILINE;

ADJUVANT THERAPY; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; INSOMNIA; LIVER TOXICITY; MONOTHERAPY; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; STUDY DESIGN; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84884190046     PISSN: None     EISSN: 20479158     Source Type: Journal    
DOI: 10.1186/2047-9158-2-19     Document Type: Review

References (62)

1. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
2. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
3. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochemistry 1986, 46:1359-1365.
4. Cohen G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacology 1984, 106:209-210.
5. Finnegan KT, Skratt JJ, Irwin I, et al. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 1990, 184:119-126.
6. Knollema S, Aukema W, Hom H, et al. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 1995, 26:1883-1887.
7. de la Cruz CP, Revilla E, Steffen V, et al. Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl. Br J Pharmacol 1996, 117:1756-1760.
8. Munirathinam S, Lakshmana MK, Raju TR. (-) deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures. Neurodegeneration 1996, 5:161-167.
9. Mytilineou C, Radcliffe P, Leonardi EK, et al. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 1997, 68:33-39.
10. Maruyama W, Takahashi T, Naoi M. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 1998, 70:2510-2515.
11. Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 2002, 301:753-764.
12. Kamada T, Chow T, Hiroi T, et al. Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet 2002, 17:199-206.
13. Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328:176-183. Parkinson Study Group.
14. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 1998, 51:520-525.
15. Turnbull K, Caslake R, Macleod A, et al. Monoamine oxidase B inhibitor for early Parkinson's disease. Cochrane Database Syst Rev 2005, (3). 10.1002/14651858. CD004898.pub2.
16. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006, 66:1200-6.
17. Larsen JP, Boas J, Erdal JE, et al. Does selegiline modify the progression of early Parkinson's disease? Results from a five year study. Eur J of Neurol 1999, 6:539-47.
18. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained Deprenyl (Selegiline) in levodopa treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 2002, 51:604-12.
19. Przunztek H, Conrad B, Dichgans J, et al. SELEDO: a 5 years long term trial on effect of selegiline in early parkinsonian patients treated with levodopa. Eur J of Neurol 1999, 6:141-50.
20. LeWitt PA, Taylor DC. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics 2008, 5:210-25.
21. Parkinson Study Group Effect of Lazabemide on the progression of disability in early parkinson's disease. Ann Neurol 1996, 40:99-107. Parkinson Study Group.
22. The development of lazabemide ('Tempium'; Roche) has been stopped. React Wkly 1999, 772:3.
23. Finberg JP, Youdim MB. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002, 43:1110-8.
24. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005, 45:878-94.
25. Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010, 92:330-44.
26. Youdim MB, Gross A, Finberg JP. Rasagiline (N-propargyl-1R(+)-aminoindan), a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001, 132:500-6.
27. Finberg JP, Youdim MB. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol 1985, 85:541-6.
28. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005, 62:241-8. Parkinson Study Group.
29. Rascol O, Brooks DJ, Melamed E, et al. LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365:947-54.
30. Parkinson Study Group A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002, 59:1937-43. Parkinson Study Group.
31. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61:561-6. Parkinson Study Group.
32. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008, 23:2194-201.
33. Shults CW. Reexamination of the TEMPO Study. Arch Neurol 2005, 62:1320.
34. Hauser RA, Lew MF, Hurtig HI, et al. TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009, 24:564-73.
35. Olanow CW, Rascol O, Hauser R, et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-78.
36. Schwarzschild MA. Rasagiline in Parkinson's disease. N Engl J Med 2010, 362:658.
37. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?. Neurology 2010, 74:1143-8.
38. Youdim MB. Rasagiline in Parkinson's disease. N Engl J Med 2010, 362:657-8.
39. Olanow CW, Rascol O. Rasagiline in Parkinson's disease. N Engl J Med 2010, 362:658-9.
40. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The ropinirole study group. Neurology 1997, 49:393-9.
41. Parkinson Study Group Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000, 284:1931-8. Parkinson Study Group.
42. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998, 13:885-94.
43. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009, 132:2947-57.
44. Louis ED, Tang MX, Cote L, et al. Progression of parkinsonian signs in Parkinson disease. Arch Neurol 1999, 56:334-7.
45. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord 2000, 15:479-84.
46. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001, 58:1611-5.
47. Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society UPDRS revision task force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008, 23:2129-70.
48. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007, 22:1061-8.
49. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22:1689-707.
50. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-508.
51. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 2006, 59:559-62.
52. Calabresi P, Mercuri NB, Sancesario G, et al. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993, 116:433-52.
53. Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009, 72(Suppl 2):S32-8.
54. Zigmond MJ, Acheson AL, Stachowiak MK, et al. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984, 41:856-61.
55. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005, 128:2777-85.
56. Graham WC, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res 1990, 514:92-102.
57. Joyce JN, Marshall JF, Bankiewicz KS, et al. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 1986, 382:360-4.
58. Fan KY, Bauferton J, Surmeier DJ, et al. Proliferation of external globus pallidus-subthalamic nucleus synapses following degeneration of midbrain dopamine neurons. J Neurosci 2012, 32:13718-28.
59. Obeso JA, Rodriguez-Oroz MC, Lanciego JL. el al. How does Parkinson's disease begin? The role of compensatory mechanisms. Trends Neurosci 2004, 27:125-7.
60. Obeso JA, Schapira AH. Compensatory mechanisms in Parkinson's disease. Mov Disord 2009, 24:153-4.
61. Selegiline hydrochloride (package insert) 2009, Morgantown, West Virginia: Mylan Pharmaceuticals.
62. Azilect (package insert) 2008, Kfar-Saba, Israel: Teva Pharmaceutical.